Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization.
Grant
M B
MB
Department of Medicine, College of Medicine, University of Florida, Gainesville 32610.
Caballero
S
S
Millard
W J
WJ
D001483:Base Sequence; D015139:Blotting, Southern; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002633:Chemotaxis / Q000187:drug effects; D017364:Collagenases / Q000096:biosynthesis; D004247:DNA / Q000096:biosynthesis; D017931:DNA Primers; D003930:Diabetic Retinopathy / Q000473:pathology; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000473:pathology; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism / Q000494:pharmacology*; D008297:Male; D008969:Molecular Sequence Data; D009389:Neovascularization, Pathologic / Q000503:physiopathology* / Q000628:therapy; D015282:Octreotide / Q000494:pharmacology*; D017395:Plasminogen Activator Inhibitor 1 / Q000096:biosynthesis; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000494:pharmacology; D012171:Retinal Vessels; D010959:Tissue Plasminogen Activator / Q000096:biosynthesis; D014158:Transcription, Genetic / Q000187:drug effects
D017931:DNA Primers; D017395:Plasminogen Activator Inhibitor 1; D010982:Platelet-Derived Growth Factor; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2; D007334:Insulin-Like Growth Factor I; D004247:DNA; D010959:Tissue Plasminogen Activator; D017364:Collagenases; D015282:Octreotide